POLYSTYRENE SULFONATE , OMNIPAQUE 300 mg I/ml soluzione iniettabile, Placebo, Veltassa 8.4 g powder for oral suspension clinical trials

A Prospective, double-blind, randomized, single centre trial to evaluate the rate of RAAS inhibitor withdrawal or down-titration in non-dialysis patients with CKD stage IIIB to Vrandomized to Patiromer or placebo

This study looks at how a new medicine, Patiromer, affects potassium levels in people with kidney disease who are also taking blood pressure medication. High potassium can be a problem, so researchers want to see if Patiromer helps patients keep taking their important blood pressure drugs.